University Clinic Golnik — Clinical Trial Site

9 Registered trials

2 Currently recruiting

Organisation

University Clinic Golnik

Location

Golnik, Slovenia

Identifier

ORG-100031194

Address

Golnik 36, 4204, Slovenia

Departments

6801: Pulmonology
Cardiology
ICU
Medical Oncology Unit
Not applicable
Oncology
Pulmonology Department 100
pulomolgy and alergology

Clinical trials at this site (9)

Search interface

A study to test whether vicadrostat (BI 690517) in combination with empagliflozin helps people with heart failure. Recruiting

2023-509706-30-00 Heart failure (HF) 5 2024-10-18
A follow-up study to test long-term treatment with BI 1015550 in people with pulmonary fibrosis who took part in a previous study with BI 10… Recruiting

2023-507353-15-00 idiopathic pulmonary fibrosis (IPF) 5 2024-09-10
A Phase 3 study of belrestotug plus dostarlimab compared with placebo plus pembrolizumab in previously untreated PD L1 high NSCLC Ended

2023-504753-12-00 Lung Cancer, Non-Small Cell 5 2024-10-01
Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP) Ended

2023-507889-89-00 Respiratory tract infection 5 2016-02-19
A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study to Assess Efficacy and Safety of Atuliflapon Given Orally Once Daily for Twel… Ended

2023-509243-27-00 Moderate-to-Severe Uncontrolled Asthma 4 2023-04-12
A study to find out whether BI 1015550 improves lung function in people with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) Ended

2024-512803-37-00 Progressive Fibrosing Interstitial Lung Diseases (PF-IL 5 2022-10-05
Non-inferiority study of GSK3511294 (depemokimab) compared with mepolizumab or benralizumab in participants with severe asthma with an eosin… Ended

2023-510230-84-00 Severe asthma with an eosinophilic phenotype 5 2021-05-28
A Study Evaluating the Efficacy and Safety of Neoadjuvant Treatment with Atezolizumab or Placebo in Combination with Platinum-Based Chemothe… Ended

2023-504209-35-00 Early-Stage Resectable Non-small cell lung cancer (NSCL 5 2018-04-04
A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC af… Ended

2023-509137-39-00 Stage IB (T ≥ 4 cm), II and IIIA NSCLC 5 2015-11-06